Clinical effects of indacaterol in patients with COPD

Clinical effects of indacaterol in patients with COPD - Clinical effects of indacaterol in patients with COPD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006724

Enrollment

Registered

2011-11-14

Start date

2011-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Interventions

Indacaterol treatment group Onbrez breezhaler (150) 1 inhalation once daily Treatment period 4 months Tiotropium treatment group Spiriva handihaler (18) inhalation once daily Treatment period 4 m

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: COPD patients meet the GOLD guideline (post-bronchodilator FEV1/FVC <70%)

Exclusion criteria

Exclusion criteria: 1) Asthma 2) Subjects who have been treated with LABA or anti-cholinergic agents 3) Subjects have been shown exacervations 4) Patients judged to be unsuitable by the doctors

Design outcomes

Primary

Measure	Time frame
Indices of chest CT	—

Secondary

Measure	Time frame
Parameters of pulmonary function Cell counts of induced sputum Scores of quality of life	—

Countries

Japan

Contacts

Public ContactMakoto Hoshino

Atami Hospital International University of Health and Welfare Department of Respiratory Medicine

0557-81-9171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026